Congress Publications

Efficacy and safety of obefazimod in patients with moderately to severely active ulcerative colitis: results from the Phase 3, randomized, double-blind, placebo-controlled, 44-week maintenance trial (ABTECT-Maintenance)

Obefazimod increases miR-124 expression to consistently modulate inflammation and fibrosis across preclinical models

Long-term efficacy and persistence with obefazimod after dose de-escalation to 25 mg: 3-year interim analysis in patients with moderately to severely active ulcerative colitis completing Week 144, stratified by prior advanced therapy experience: results from the Phase 2 program

Efficacy of obefazimod in Phase 3 ABTECT-Maintenance trial: results of 44-week therapy in subsets of patients with and without prior inadequate response to advanced therapies

Efficacy, persistence, and safety of obefazimod in patients with moderately to severely active ulcerative colitis: 3-year interim analysis following dose de-escalation to 25 mg in the open-label maintenance Phase 2 study

Symptoms of bowel urgency and nocturnal bowel movements are linked with improvement in clinical outcomes among patients with moderately to severely active ulcerative colitis treated with obefazimod: pooled results from the 8-week ABTECT Phase 3 induction trials

Obefazimod reduces inflammation-driven tumor burden in a murine model of colitis-associated cancer

Improvements in bowel urgency and nocturnal bowel movements among patients with moderately to severely active ulcerative colitis treated with obefazimod induction therapy: pooled results from the ABTECT-1 and ABTECT-2 Phase 3 trials

Rapid and progressive improvement with obefazimod in ulcerative colitis in the ABTECT induction program: subgroup analysis by prior advanced therapy failure status and therapeutic class

Efficacy of obefazimod across baseline disease extent and endoscopic severity in ulcerative colitis: Phase 3 ABTECT induction results

Favorable safety profile of obefazimod with no increased risk of infection: integrated analysis of the Phase 3 induction trials in ulcerative colitis

Impact of obefazimod treatment on histologic and combined histologic-endoscopic outcomes in patients with moderately to severely active UC: results from the ABTECT-1 and ABTECT-2 Phase 3, double-blind, placebo-controlled induction trials

Early symptomatic improvement with obefazimod in patients with moderately to severely active ulcerative colitis: pooled results from the ABTECT-1 and ABTECT-2 Phase 3, double-blind, placebo-controlled induction trials

Efficacy and safety of obefazimod in an elderly population with moderately to severely active ulcerative colitis: week 8 results from the ABTECT-1 and ABTECT-2 Phase 3, double-blind, placebo-controlled induction trials

Efficacy of obefazimod in patients with moderately to severely active ulcerative colitis: results in subgroups of prior inadequate response to advanced therapy (ATIR) including or excluding patients with prior JAK-IR from ABTECT Phase 3 induction trials

Integrated summary of safety of obefazimod in Phase 3 ABTECT induction trials

Improvements in patient-reported fatigue among patients with moderately to severely active ulcerative colitis (UC) treated with obefazimod: pooled results from the 8-week ABTECT-1 and ABTECT-2 Phase 3 double-blind, placebo-controlled induction trials

Improvements in patient-reported, disease-specific, and overall quality-of-life among patients with moderately to severely active ulcerative colitis (UC) treated with obefazimod: pooled results from the 8-week ABTECT-1 and ABTECT-2 phase 3 induction trials

Obefazimod shows first evidence of dual
anti-inflammatory and anti-fibrotic activity
in murine in vivo and human in vitro models

Obefazimod enhances miR-124 expression in blood and colon tissue and reduces the key inflammatory cytokines IL-17A and IL-6 in serum of patients with moderate-to-severely active ulcerative colitis: results from the Phase 3 ABTECT induction trials

Obefazimod shows first evidence of anti-fibrotic activity in preclinical models of inflammatory bowel disease

Obefazimod induction therapy for moderately to severely active ulcerative colitis: pooled analysis of inflammatory biomarkers from the two ABTECT Phase 3 double-blind, placebo-controlled induction trials

Impact of baseline disease extent on efficacy of obefazimod in patients with moderately to severely active ulcerative colitis: pooled results from ABTECT-1 and ABTECT-2 Phase 3 trials

Improvements in patient-reported, disease-specific, and overall quality-of-life among patients with moderately to severely active ulcerative colitis (UC) treated with obefazimod induction therapy: pooled results from the 8-week ABTECT-1 and ABTECT-2 Phase 3, double-blind, placebo-controlled induction trials

Impact of baseline disease duration on the efficacy of once-daily oral obefazimod in moderately to severely active ulcerative colitis: week 8 results from the ABTECT-1 and ABTECT-2 Phase 3 trials

Improvements in patient-reported fatigue among patients with moderately to severely active UC treated with obefazimod induction therapy: pooled results from the 8-week ABTECT-1 and ABTECT-2 Phase 3 trials

Impact of concomitant corticosteroid use on efficacy and safety of obefazimod at week 8 in moderately to severely active UC

Pooled analysis of efficacy and safety of once-daily oral obefazimod in North American patients from the ABTECT Phase 3, double-blind, placebo-controlled induction trials

Integrated summary of safety of obefazimod in Phase 3 ABTECT induction trials

Improvements in patient-reported bowel urgency and nocturnal bowel movements among patients with moderately to severely active UC treated with obefazimod induction therapy

Impact of prior inadequate response to advanced therapies on early symptomatic improvement with obefazimod induction in moderately to severely active UC

Continued efficacy improvement beyond induction with once-daily obefazimod: week 8–48 outcomes from the Phase 2b open-label maintenance study, stratified by prior advanced-therapy exposure

Obefazimod enhances miR-124 expression in blood and colon tissue, and reduces IL-17A and IL-6 in serum of patients with moderate-to-severely active UC

Impact of prior inadequate response to advanced therapy (ATIR) on the efficacy of obefazimod in patients with moderately to severely active UC

Impact of prior advanced therapy inadequate response by drug class on symptomatic improvement with obefazimod in patients with moderately to severely active ulcerative colitis: pooled analysis of ABTECT Phase 3 induction trials

Impact of obefazimod treatment on histologic and combined histologic-endoscopic outcomes in patients with moderately to severely active UC

Early symptomatic improvement with obefazimod in patients with moderately to severely active ulcerative colitis: pooled results from the ABTECT-1 and ABTECT-2 Phase 3, double-blind, placebo-controlled induction trials

Improvements in patient-reported work productivity and activity impairment among patients with moderately to severely active UC treated with obefazimod induction therapy

Impact of baseline Mayo endoscopic subscore on the efficacy of once-daily oral obefazimod in moderately to severely active UC

Impact of baseline body mass index (BMI) on efficacy of obefazimod in patients with moderately to severely active UC

Impact of age on the efficacy and safety of once-daily oral obefazimod in moderately to severely active UC

Pooled analysis of efficacy and safety of once-daily oral obefazimod in European patients from the ABTECT Phase 3, double-blind, placebo-controlled induction trials